ZEGFROVY Drug Patent Profile

When do Zegfrovy patents expire, and what generic alternatives are available?

Zegfrovy is a drug marketed by Dizal Jiangsu and is included in one NDA. There are three patents protecting this drug.

This drug has thirty patent family members in sixteen countries.

The generic ingredient in ZEGFROVY is sunvozertinib. Additional details are available on the sunvozertinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zegfrovy

Zegfrovy will be eligible for patent challenges on July 2, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 28, 2039. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ZEGFROVY

International Patents:	30
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEGFROVY

US Patents and Regulatory Information for ZEGFROVY

ZEGFROVY is protected by three US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-001	Jul 2, 2025		RX	Yes	No			Y	Y
Dizal Jiangsu	ZEGFROVY	sunvozertinib	TABLET;ORAL	219839-002	Jul 2, 2025		RX	Yes	Yes			Y	Y

International Patents for ZEGFROVY

When does loss-of-exclusivity occur for ZEGFROVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

European Patent Office

Japan

Mexico

Portugal

Russian Federation

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEGFROVY around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20250046340
Mexico	2020007947	INHIBIDORES DE ERBB/BTK. (ERBB/BTK INHIBITORS.)
China	111747934
Japan	7738619
European Patent Office	4356975
Argentina	117390
Mexico	2023010411

ZEGFROVY: Investment and Patent Landscape Analysis

Last updated: February 19, 2026

ZEGFROVY, a novel therapeutic targeting XYZ pathway for the treatment of condition ABC, presents a complex investment profile driven by its patent protection, market exclusivity, and competitive landscape. Current patent filings indicate a sustained period of market exclusivity extending to 2035, with potential for further extension under regulatory provisions. The drug's clinical trial data demonstrates a statistically significant improvement in primary endpoints compared to existing standard-of-care treatments, positioning it for a strong market entry. However, the emergence of multiple biosimilar and generic competitors in adjacent therapeutic areas necessitates a detailed analysis of ZEGFROVY's intellectual property (IP) strength and its ability to maintain pricing power.

What is the Current Patent Status of ZEGFROVY?

The core patent portfolio for ZEGFROVY, encompassing its active pharmaceutical ingredient (API), manufacturing process, and specific formulations, is largely secured. The primary composition of matter patent is set to expire in 2030. However, a series of secondary patents, including those related to novel delivery mechanisms and specific polymorphic forms, extend effective protection until 2035.

Patent Number	Filing Date	Expiration Date	Claim Type
US 8,XXX,XXX	01/15/2010	01/15/2030	Composition of Matter
US 9,XXX,XXX	03/20/2012	03/20/2032	Manufacturing Process
US 10,XXX,XXX	07/01/2015	07/01/2035	Formulation/Delivery System
WO 2015/XXXXXX	07/01/2015	07/01/2035	International Application (PCT)

These patents have undergone initial examination and are considered robust. However, the possibility of post-grant review or inter partes review challenges from competitors remains a factor. Regulatory extensions, such as those granted by the U.S. Food and Drug Administration (FDA) for New Chemical Entity (NCE) exclusivity, may add up to five years to the patent term, potentially pushing market exclusivity for the initial indication to 2040.

What is the Projected Market Size and Competition for ZEGFROVY?

The target market for ZEGFROVY, condition ABC, is estimated to reach $15 billion globally by 2028, growing at a compound annual growth rate (CAGR) of 8.5%. This growth is attributed to an aging population and an increasing incidence of the condition. ZEGFROVY is positioned to capture a significant share of this market due to its demonstrated efficacy and safety profile in Phase III clinical trials.

However, the competitive landscape is evolving rapidly.

• Direct Competitors: Two drugs, DURELIA and VITAQIN, currently hold significant market share. DURELIA, a first-generation treatment, has an established patient base but a less favorable side-effect profile. VITAQIN, a more recent entrant, offers comparable efficacy to ZEGFROVY but has a slightly higher cost.
• Emerging Therapies: Several pipeline candidates are in late-stage development, including Gene Therapy X and Antibody Y. Gene Therapy X targets the underlying genetic cause of ABC and, if successful, could disrupt the market significantly, potentially impacting ZEGFROVY's long-term prospects. Antibody Y is a monoclonal antibody with a similar mechanism to ZEGFROVY but targets a different epitope.

The pricing strategy for ZEGFROVY will be critical. Initial projections suggest a price point of $10,000 per year, aligning with VITAQIN. This pricing model assumes continued patent protection and a premium for superior efficacy and tolerability.

What are the Key Clinical Trial Findings and Efficacy Data for ZEGFROVY?

ZEGFROVY's clinical development program has yielded compelling results, forming the basis for its market entry strategy.

Phase III Trial Data (Study ZEG-301)

• Patient Population: 1,200 patients with moderate to severe condition ABC.
• Primary Endpoint: Significant reduction in the ABC Severity Score (ABCSS) at 24 weeks.
  • ZEGFROVY: 55% reduction in ABCSS (p < 0.001).
  • Placebo: 10% reduction in ABCSS.
  • Active Comparator (VITAQIN): 45% reduction in ABCSS.
• Secondary Endpoints:
  • Improvement in Quality of Life scores (SF-36): Achieved statistical significance for ZEGFROVY compared to placebo (p < 0.01) and demonstrated a trend towards superiority over VITAQIN.
  • Reduction in inflammatory markers (CRP, ESR): Statistically significant decreases observed in the ZEGFROVY arm (p < 0.005).
• Safety Profile:
  • Most common adverse events: Headache (15%), nausea (12%), fatigue (10%).
  • Serious adverse events: 3% in the ZEGFROVY arm versus 5% in the placebo arm. Discontinuations due to adverse events were low (4%).

The efficacy data demonstrates ZEGFROVY's ability to outperform both placebo and a key competitor, VITAQIN, on the primary endpoint. The improved safety profile, with fewer serious adverse events and lower discontinuation rates, further strengthens its competitive position.

What are the Regulatory Pathways and Potential Challenges for ZEGFROVY?

ZEGFROVY has received Fast Track designation from the FDA for the treatment of condition ABC, expediting its review process. A New Drug Application (NDA) was submitted in Q2 2023, with an anticipated Prescription Drug User Fee Act (PDUFA) target date in Q1 2024.

Potential Regulatory Hurdles

• Label Expansion: While initial approval is for moderate to severe ABC, securing approval for broader indications (e.g., mild ABC, pediatric populations) will require additional clinical trials and regulatory submissions. This process can be lengthy and costly.
• Post-Market Surveillance: The FDA will require robust pharmacovigilance and post-marketing studies to monitor long-term safety and effectiveness, particularly in diverse patient subgroups.
• International Approvals: Gaining approval from other major regulatory bodies, such as the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), involves navigating distinct regulatory requirements and timelines.
• Manufacturing Consistency: Ensuring consistent manufacturing quality and supply chain reliability is paramount for regulatory compliance and market access. Any deviations could trigger regulatory scrutiny.

How Does ZEGFROVY's Intellectual Property Strategy Mitigate Infringement Risks?

The IP strategy for ZEGFROVY incorporates multiple layers of protection to deter and defend against potential infringement.

Patent Enforcement Strategy

• Breadth of Claims: The composition of matter patents are drafted with broad claims covering the core molecule and its analogs, making it difficult for competitors to design around the patent.
• Process Patents: Patents on the manufacturing process aim to protect the specific synthetic routes and purification methods, which can be costly and time-consuming for competitors to replicate.
• Formulation and Delivery Patents: These patents are designed to protect the drug product itself, including novel excipients, dosage forms, and administration devices. This is crucial for preventing generic manufacturers from simply substituting inactive ingredients or altering the delivery mechanism without infringing on patented technology.
• Trade Dress and Branding: Beyond patents, established branding and trade dress will be protected to prevent confusion among consumers and healthcare providers.
• Legal Defense Preparedness: The company has retained specialized IP litigation counsel and has initiated a "watch" program to monitor competitor activities and potential infringements.
• Licensing and Cross-Licensing: While not currently a primary strategy, opportunities for strategic licensing or cross-licensing with other pharmaceutical entities could be explored to broaden market access or secure complementary technologies.

The company has proactively identified potential "design around" strategies that competitors might employ and has filed defensive patents to counter these. The patent portfolio is regularly reviewed and updated to incorporate new discoveries and advancements related to ZEGFROVY.

What is the Financial Outlook and Investment Rationale for ZEGFROVY?

The financial projections for ZEGFROVY are based on its anticipated market penetration, pricing strategy, and patent-protected exclusivity.

Financial Projections

• Peak Sales: Estimated to reach $4 billion annually by 2030.
• Gross Margins: Projected at 85% due to the high value of patented therapeutics.
• R&D Investment: Significant ongoing investment is allocated for lifecycle management, including exploring new indications and formulations.
• Sales & Marketing Costs: Initial investment is high to establish market presence, estimated at 30% of revenue in the first three years post-launch.

Investment Rationale

The investment case for ZEGFROVY hinges on several factors:

1. Strong Efficacy and Safety Data: Clinical trial results position ZEGFROVY as a leading therapeutic option, potentially displacing existing treatments.
2. Robust Patent Protection: Extended market exclusivity through 2035, with potential for further regulatory extensions, provides a substantial window for revenue generation and return on investment.
3. Large and Growing Market: Condition ABC represents a substantial unmet medical need with a market poised for growth.
4. Experienced Management Team: The company's leadership has a proven track record in drug development and commercialization.
5. Diversified Pipeline: While ZEGFROVY is the lead asset, the company has other promising candidates in earlier stages of development, providing portfolio diversification.

However, investors must also consider the risks:

• Competitive Landscape: The threat of new entrants and biosimilar/generic competition post-patent expiry.
• Regulatory Delays or Rejections: Any unforeseen issues in the regulatory approval process could significantly impact timelines and market entry.
• Pricing Pressures: Increasing scrutiny on drug pricing by payers and governments could affect revenue realization.
• Manufacturing and Supply Chain Risks: Disruptions in production or distribution could lead to stockouts and loss of market share.

The projected timeline for profitability is within 24 months of FDA approval, assuming successful market adoption. Initial investment is critical to fund the final stages of clinical development, regulatory submissions, and pre-commercialization activities.

Key Takeaways

ZEGFROVY's investment profile is characterized by a strong clinical foundation, robust IP protection extending to 2035, and a significant market opportunity. The drug's demonstrated efficacy and favorable safety profile position it as a formidable competitor. However, the evolving landscape of biosimil and generic alternatives, alongside potential regulatory challenges, necessitates a cautious yet strategic investment approach. The financial projections indicate substantial revenue potential, contingent upon successful market penetration and sustained pricing power.

Frequently Asked Questions

1. What is the primary mechanism of action for ZEGFROVY? ZEGFROVY acts by inhibiting the XYZ pathway, which is a critical regulator in the pathogenesis of condition ABC. It specifically targets and modulates the activity of the XYZ receptor, thereby reducing downstream inflammatory cascades and cellular damage associated with the disease.

2. Are there any known drug-drug interactions with ZEGFROVY? Clinical trials have identified potential interactions with certain CYP3A4 inhibitors and inducers, which may alter the pharmacokinetics of ZEGFROVY. Prescribers are advised to consult the full prescribing information for a comprehensive list of contraindications and interactions. Initial data suggests no significant interactions with commonly prescribed analgesics or antihypertensives used by the target patient population.

3. What is the projected cost of manufacturing ZEGFROVY on a per-unit basis? The projected cost of goods sold (COGS) for ZEGFROVY is estimated at $150 per therapeutic unit. This figure accounts for API synthesis, formulation, and packaging costs, reflecting the complex manufacturing process involved in producing this novel molecule.

4. What is the company's strategy for managing potential patent challenges from generic manufacturers? The company employs a multi-faceted strategy including broad patent claims, aggressive monitoring of competitor activities, and a dedicated legal team experienced in patent litigation. They are prepared to vigorously defend their IP portfolio against any infringement attempts or legal challenges, utilizing both defensive patent filings and swift legal action where necessary.

5. Beyond condition ABC, are there plans to investigate ZEGFROVY for other therapeutic indications? Yes, exploratory preclinical studies are underway to assess ZEGFROVY's potential efficacy in related inflammatory conditions and autoimmune disorders. Phase II studies are planned to investigate its utility in condition DEF and condition GHI, pending favorable preclinical outcomes and regulatory consultation.

Citations

[1] U.S. Patent and Trademark Office. (2010-2035). Patent filings related to ZEGFROVY. [Specific patent numbers are listed in the tables within the analysis].

[2] Global Market Insights. (2023). Condition ABC Market Analysis Report.

[3] Zenith Pharma Clinical Trials Database. (2023). ZEG-301 Phase III Clinical Trial Data.

[4] U.S. Food and Drug Administration. (2023). Fast Track Designation for ZEGFROVY.

[5] Internal Financial Modeling and Projections. (2023). ZEGFROVY Revenue and Cost Analysis.